Bacillus Calmette-Guérin therapy for high-risk superficial bladder cancer.

Twelve consecutive patients with carcinoma in situ (CIS) and 17 with T1G3 transitional cell cancer of the bladder were given intravesical Bacillus Calmette-Guérin (BCG) therapy after transurethral resection of all visible lesions. BCG (150 mg in 50 ml normal saline) was given once weekly for 12 weeks and then once monthly for 6 months. The median follow-up was 2.